Call for a Free Consultation —— Home Attorneys Jonathan F. Marshall Tom Martin Colin E. Bonus Daniel M. Paul Koutouzakis Matthew J. Call Us Locations Live Chat. Manufacturing or Distributing Imitation Marijuana If you were arrested for possession with intent to distribute synthetic marijuana or distribution of this variety of CDS, you are facing prosecution in accordance with N. This law provides that: NJ Statute: 2C Criminalization, degree of crime.
Whereas, the General Assembly finds that there is a growing use of the unregulated synthetic cannabinoids commonly known as K2 or synthetic marijuana; and. Whereas, preliminary studies indicate that synthetic cannabinoid substances unregulated in North Carolina are from three to over times more potent than THC, the active ingredient found in marijuana; and.
Whereas, many states have already included one or more of these chemical compounds on schedules of controlled substances, but none of these chemicals are currently listed on North Carolina's schedule of controlled substances; and.
Whereas, synthetic cannabinoids are referred to as the new marijuana, and K2 is gaining in popularity at an alarming rate among high school and college students and persons on probation and parole; and. Whereas, while having the same or stronger physiological effects as high potency marijuana, synthetic marijuana or K2 does not show a positive reading in a urinalysis test, which adds to the desirability and increased growth among drug abusers and increases the threat to public health and safety by avoiding detection; and.
Whereas, the General Assembly should address the growing threat of synthetic cannabinoids to the health, safety, and welfare of our citizens before the problem becomes epidemic in the State of North Carolina; Now, therefore,. Schedule VI controlled substances. This schedule includes the controlled substances listed or to be listed by whatever official name, common or usual name, chemical name, or trade name designated.
In determining that such substance comes within this schedule, the Commission shall find: no currently accepted medical use in the United States, or a relatively low potential for abuse in terms of risk to public health and potential to produce psychic or physiological dependence liability based upon present medical knowledge, or a need for further and continuing study to develop scientific evidence of its pharmacological effects.
AB Effective January 1, AB Effective April 4, Operative October 1, , by Sec. Note: This section was added on November 8, , by initiative Proposition Section B To ensure that patients and their primary caregivers who obtain and use marijuana for medical purposes upon the recommendation of a physician are not subject to criminal prosecution or sanction.
C To encourage the federal and state governments to implement a plan to provide for the safe and affordable distribution of marijuana to all patients in medical need of marijuana. Added November 5, , by initiative Proposition , Sec. If the Regents of the University of California, by appropriate resolution, accept this responsibility, the University of California shall create a program, to be known as the California Cannabis Research Program, hosted by the Center for Medicinal Cannabis Research.
The studies may examine the effect of cannabis on motor skills, the health and safety effects of cannabis, cannabinoids, and other related constituents, and other behavioral and health outcomes. Program requirements to be used when evaluating responses to its solicitation for proposals shall include, but not be limited to, all of the following:.
The proposal may also include research on other serious illnesses, provided that resources are available and medical information justifies the research. Peer reviewers shall be selected for their expertise in the scientific substance and methods of the proposed research, and their lack of bias or conflict of interest regarding the applicants or the topic of an approach taken in the proposed research.
Peer reviewers shall judge research proposals on several criteria, foremost among which shall be both of the following:. The campuses at which research under the auspices of the program is to take place shall accommodate the administrative offices, including the director of the program, as well as a data management unit, and facilities for detection and analysis of various naturally occurring and synthetic cannabinoids, as well as storage of specimens. Criteria for selection of research locations shall include the elements listed in subdivision b and, additionally, shall give particular weight to the organizational plan, leadership qualities of the program director, and plans to involve investigators and patient populations from multiple sites.
As the first wave of studies is completed, it is anticipated that the program will receive requests for funding of additional studies. These requests shall be reviewed by the Scientific Advisory Council. The program shall consult with the Research Advisory Panel analogous agencies in other states, and appropriate federal agencies in an attempt to avoid duplicative research and the wasting of research dollars. Cannabis used by the program may be obtained from the National Institute on Drug Abuse or any other entity authorized by the appropriate federal agencies, the Attorney General pursuant to Section , or may be cultivated by the program pursuant to applicable federal and state laws and regulations.
The program may add research on other serious illnesses, provided that resources are available and medical information justifies the research. The studies shall focus on comparisons of both the efficacy and safety of methods of administering the drug to patients, including inhalational, tinctural, and oral, evaluate possible uses of cannabis as a primary or adjunctive treatment, and develop further information on optimal dosage, timing, mode of administration, and variations in the effects of different cannabinoids and varieties of cannabis or synthetic compounds that simulate the effects of naturally occurring cannabinoids.
The studies may also focus on examining testing methods for detecting harmful contaminants in cannabis, including, but not limited to, mold, bacteria, and mycotoxins that could cause harm to patients. The program shall not expend more than 5 percent of its General Fund allocation in efforts to obtain money from outside sources. In no case shall the program accept funds that are offered with any conditions other than that the funds be used to study the efficacy and safety of cannabis as part of medical treatment.
The interim reports required under this paragraph shall include, but not be limited to, data on all of the following:. A The names and number of diseases or conditions under study. B The number of patients enrolled in each study, by disease. C Any scientifically valid preliminary findings.
Members shall be chosen on the basis of scientific expertise. Members of the council shall serve on a voluntary basis, with reimbursement for expenses incurred in the course of their participation.
The members shall be reimbursed for travel and other necessary expenses incurred in their performance of the duties of the council. AB Effective October 12, Note: Sections
0コメント